Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery

Michael Y M Chen, Caroline Chiles, Brian W. Loggie, Robert H. Choplin, Mark A. Perini, Ronald A. Fleming

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: The purpose of this study was to determine the incidence and severity of thoracic reactions in patients undergoing intraperitoneal heated chemotherapy (IPHC). Methods: Forty-two patients who had intraperitoneal disseminated malignancies were treated with cytoreductive surgery (CS) and IPHC. The primary malignancies included carcinoma of the colon (n = 17), stomach (n = 6), appendix (n = 6), pseudomyxoma peritonei (n = 3), mesothelium (n = 2), ovaries (n = 2), jejunum (n = 2), gallbladder (n = 1), urachus (n = 1), and peritoneal carcinomatosis (n = 2). After CS, IPHC with mitomycin (MMC) was administered by perfusion at 40.5°C. After IPHC, multiple radiographs of the chest were reviewed in comparison to the control group. Results: Thoracic complications occurred in 36 patients (86%), including atelectasis in 32 patients (76%), pleural effusions in 27 (64%), pulmonary edema in 10 (24%), pneumonia in 2 (5%), and pneumothorax in 2 (5%). The incidence of thoracic complications in the IPHC group was significantly higher than that of patients in the control group (P <.05). Correlations between the prevalence of pleural effusion and the dose of MMC, duration of procedure, and presence of thrombocytopenia were not significant (P > .05). Conclusions: Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention.

Original languageEnglish
Pages (from-to)19-23
Number of pages5
JournalJournal of Surgical Oncology
Volume66
Issue number1
DOIs
StatePublished - Sep 1997
Externally publishedYes

Fingerprint

Mitomycin
Thorax
Drug Therapy
Pulmonary Atelectasis
Pleural Effusion
Urachus
Pseudomyxoma Peritonei
Carcinoma
Control Groups
Incidence
Appendix
Pneumothorax
Pulmonary Edema
Jejunum
Gallbladder
Ovary
Neoplasms
Pneumonia
Stomach
Colon

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. / Chen, Michael Y M; Chiles, Caroline; Loggie, Brian W.; Choplin, Robert H.; Perini, Mark A.; Fleming, Ronald A.

In: Journal of Surgical Oncology, Vol. 66, No. 1, 09.1997, p. 19-23.

Research output: Contribution to journalArticle

Chen, Michael Y M ; Chiles, Caroline ; Loggie, Brian W. ; Choplin, Robert H. ; Perini, Mark A. ; Fleming, Ronald A. / Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. In: Journal of Surgical Oncology. 1997 ; Vol. 66, No. 1. pp. 19-23.
@article{c575daba23914972859f802d76480465,
title = "Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery",
abstract = "Background: The purpose of this study was to determine the incidence and severity of thoracic reactions in patients undergoing intraperitoneal heated chemotherapy (IPHC). Methods: Forty-two patients who had intraperitoneal disseminated malignancies were treated with cytoreductive surgery (CS) and IPHC. The primary malignancies included carcinoma of the colon (n = 17), stomach (n = 6), appendix (n = 6), pseudomyxoma peritonei (n = 3), mesothelium (n = 2), ovaries (n = 2), jejunum (n = 2), gallbladder (n = 1), urachus (n = 1), and peritoneal carcinomatosis (n = 2). After CS, IPHC with mitomycin (MMC) was administered by perfusion at 40.5°C. After IPHC, multiple radiographs of the chest were reviewed in comparison to the control group. Results: Thoracic complications occurred in 36 patients (86{\%}), including atelectasis in 32 patients (76{\%}), pleural effusions in 27 (64{\%}), pulmonary edema in 10 (24{\%}), pneumonia in 2 (5{\%}), and pneumothorax in 2 (5{\%}). The incidence of thoracic complications in the IPHC group was significantly higher than that of patients in the control group (P <.05). Correlations between the prevalence of pleural effusion and the dose of MMC, duration of procedure, and presence of thrombocytopenia were not significant (P > .05). Conclusions: Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention.",
author = "Chen, {Michael Y M} and Caroline Chiles and Loggie, {Brian W.} and Choplin, {Robert H.} and Perini, {Mark A.} and Fleming, {Ronald A.}",
year = "1997",
month = "9",
doi = "10.1002/(SICI)1096-9098(199709)66:1<19::AID-JSO5>3.0.CO;2-Q",
language = "English",
volume = "66",
pages = "19--23",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery

AU - Chen, Michael Y M

AU - Chiles, Caroline

AU - Loggie, Brian W.

AU - Choplin, Robert H.

AU - Perini, Mark A.

AU - Fleming, Ronald A.

PY - 1997/9

Y1 - 1997/9

N2 - Background: The purpose of this study was to determine the incidence and severity of thoracic reactions in patients undergoing intraperitoneal heated chemotherapy (IPHC). Methods: Forty-two patients who had intraperitoneal disseminated malignancies were treated with cytoreductive surgery (CS) and IPHC. The primary malignancies included carcinoma of the colon (n = 17), stomach (n = 6), appendix (n = 6), pseudomyxoma peritonei (n = 3), mesothelium (n = 2), ovaries (n = 2), jejunum (n = 2), gallbladder (n = 1), urachus (n = 1), and peritoneal carcinomatosis (n = 2). After CS, IPHC with mitomycin (MMC) was administered by perfusion at 40.5°C. After IPHC, multiple radiographs of the chest were reviewed in comparison to the control group. Results: Thoracic complications occurred in 36 patients (86%), including atelectasis in 32 patients (76%), pleural effusions in 27 (64%), pulmonary edema in 10 (24%), pneumonia in 2 (5%), and pneumothorax in 2 (5%). The incidence of thoracic complications in the IPHC group was significantly higher than that of patients in the control group (P <.05). Correlations between the prevalence of pleural effusion and the dose of MMC, duration of procedure, and presence of thrombocytopenia were not significant (P > .05). Conclusions: Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention.

AB - Background: The purpose of this study was to determine the incidence and severity of thoracic reactions in patients undergoing intraperitoneal heated chemotherapy (IPHC). Methods: Forty-two patients who had intraperitoneal disseminated malignancies were treated with cytoreductive surgery (CS) and IPHC. The primary malignancies included carcinoma of the colon (n = 17), stomach (n = 6), appendix (n = 6), pseudomyxoma peritonei (n = 3), mesothelium (n = 2), ovaries (n = 2), jejunum (n = 2), gallbladder (n = 1), urachus (n = 1), and peritoneal carcinomatosis (n = 2). After CS, IPHC with mitomycin (MMC) was administered by perfusion at 40.5°C. After IPHC, multiple radiographs of the chest were reviewed in comparison to the control group. Results: Thoracic complications occurred in 36 patients (86%), including atelectasis in 32 patients (76%), pleural effusions in 27 (64%), pulmonary edema in 10 (24%), pneumonia in 2 (5%), and pneumothorax in 2 (5%). The incidence of thoracic complications in the IPHC group was significantly higher than that of patients in the control group (P <.05). Correlations between the prevalence of pleural effusion and the dose of MMC, duration of procedure, and presence of thrombocytopenia were not significant (P > .05). Conclusions: Bibasilar atelectasis and pleural effusions are common findings after IPHC with MMC, but most of them do not necessarily warrant intervention.

UR - http://www.scopus.com/inward/record.url?scp=0030817091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030817091&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9098(199709)66:1<19::AID-JSO5>3.0.CO;2-Q

DO - 10.1002/(SICI)1096-9098(199709)66:1<19::AID-JSO5>3.0.CO;2-Q

M3 - Article

C2 - 9290688

AN - SCOPUS:0030817091

VL - 66

SP - 19

EP - 23

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -